Synthroid and Gabapentin Interaction: What You Need to Know

The direct answer

Levothyroxine and gabapentin can generally be taken by the same patient. Gabapentin is eliminated almost entirely unchanged by the kidneys and does not induce or inhibit the cytochrome P450 enzymes involved in thyroid hormone clearance, according to its FDA label (Neurontin prescribing information). This distinguishes it from enzyme-inducing anticonvulsants such as phenytoin and carbamazepine, which the levothyroxine label lists as agents that can increase levothyroxine clearance and require dose monitoring according to the Synthroid prescribing information. No dedicated clinical trial or pharmacokinetic study of the gabapentin-levothyroxine combination appears in the published literature; the absence of a signal is not the same as a confirmed absence of interaction, and the note below on evidence boundaries should be read alongside any clinical decision.

Why this pair comes up so often

Hypothyroidism is common enough that clinicians regularly manage it alongside other chronic conditions, and the NIDDK estimates it affects a meaningful share of U.S. adults, with prevalence rising with age (NIDDK, hypothyroidism overview). Gabapentin is one of the most frequently prescribed medications in the United States, used both on-label for postherpetic neuralgia and epilepsy and off-label for diabetic neuropathy, fibromyalgia-related pain, and other neuropathic conditions. Because both conditions increase in prevalence with age, and because gabapentin is widely prescribed for pain syndromes that co-occur with autoimmune thyroid disease, a large number of patients end up taking both drugs at the same time.

Levothyroxine has a narrow therapeutic index and is well known to be disrupted by calcium supplements, iron salts, proton pump inhibitors, sucralfate, and aluminum-containing antacids. That reputation is why patients reasonably ask whether gabapentin belongs on the same list. It does not appear to, based on mechanism and on the absence of a described interaction in clinical use, but the two drugs are different enough pharmacologically that the question is worth answering carefully rather than dismissing.

Why the mechanisms do not overlap

Gabapentin is not appreciably metabolized in the liver. Its FDA label states it is eliminated from the systemic circulation by renal excretion as unchanged drug, and that it does not measurably inhibit or induce the major CYP enzymes (1A2, 2A6, 2C9, 2C19, 2D6, 2E1, 3A4) (Neurontin label).

Levothyroxine, a synthetic form of T4, is absorbed in the jejunum and upper ileum, converted peripherally to the active hormone T3, and cleared through a combination of hepatic conjugation and biliary excretion. The Synthroid label names CYP3A4-inducing anticonvulsants such as phenytoin, carbamazepine, and phenobarbital as drugs that increase levothyroxine clearance and may require a dose adjustment according to the Synthroid prescribing information. Gabapentin is not on that list, and its lack of enzyme-inducing activity is the mechanistic reason it is grouped separately from those older anticonvulsants.

This mechanistic separation is well documented at the level of each drug's own label. What is not available is a dedicated interaction study confirming that the combination behaves as predicted in practice. That gap is worth naming plainly rather than papering over with confident language.

The absorption issue is timing, not chemistry

The practical concern with levothyroxine is rarely a specific drug-drug interaction; it is whatever happens to be in the stomach at the moment it is taken. Levothyroxine is conventionally taken on an empty stomach, separated from food and other oral medications, because calcium, iron, and certain other substances can bind T4 or alter gastric conditions enough to reduce absorption. Gabapentin has not been described as binding T4 or forming an insoluble complex with it the way calcium or iron salts do. Its own absorption is saturable and transporter-mediated in the small intestine, which is a separate pharmacokinetic detail about gabapentin rather than evidence of an effect on levothyroxine.

Because gabapentin is usually dosed multiple times a day, the practical solution is straightforward: take levothyroxine first, on an empty stomach, and wait at least 30 to 60 minutes before eating or taking the first gabapentin dose. Patients who take levothyroxine at bedtime instead should separate it from their last gabapentin dose of the day by two to four hours. Patients with malabsorption conditions (celiac disease, short bowel syndrome, prior bariatric surgery) may benefit from erring toward the longer end of that window, since their baseline levothyroxine absorption is already more fragile.

Gabapentin is not an enzyme-inducing anticonvulsant, and that distinction matters

Confusion on this point is common because gabapentin is grouped in patients' minds with other anticonvulsants that do affect thyroid hormone handling. Phenytoin, carbamazepine, and phenobarbital induce hepatic CYP3A4 and UGT enzymes, accelerating T4 clearance; clinicians managing patients on these drugs often need to increase the levothyroxine dose to maintain a stable TSH, and the Synthroid label reflects this. Gabapentin and its structural relative pregabalin do not share this enzyme-inducing mechanism, and neither drug appears on the levothyroxine label's list of clearance-increasing agents. That is a meaningful pharmacologic distinction, not a marketing one, and it is the main reason gabapentin is considered a lower-concern interaction partner than the older anticonvulsants.

What monitoring makes sense

A sensitive feedback loop governs thyroid hormone levels, so even small absorption changes can eventually show up as a TSH shift. A reasonable, conservative monitoring approach for a patient stable on levothyroxine who is starting gabapentin:

Baseline. Confirm a recent TSH, and document the levothyroxine dose, formulation (brand or generic), and time of day it is taken.

Six to eight weeks after starting gabapentin. Recheck TSH. This interval is consistent with general practice for rechecking thyroid function after any change that could plausibly affect absorption or metabolism, though it is not a gabapentin-specific requirement described in a clinical trial.

After a substantial gabapentin dose change. Gabapentin dosing ranges widely, and a significant increase or decrease is a reasonable trigger to recheck TSH within a similar window, largely because any change in a patient's overall regimen is an opportunity to confirm the levothyroxine dose is still appropriate, not because gabapentin is known to alter T4 handling.

Symptom-triggered recheck. Fatigue, weight gain, cold intolerance, and constipation overlap between undertreated hypothyroidism and gabapentin's side effect profile (somnolence and dizziness are common gabapentin effects). A TSH check, not assumption, is the way to tell the two apart.

No published cohort study specifically describing TSH stability after adding gabapentin to levothyroxine was available to verify for this article. That absence should be read as a gap in the literature, not as reassurance that no effect exists.

Side effects that can be mistaken for each other

Gabapentin's label documents somnolence, dizziness, and some weight gain as common adverse effects in its studied populations (epilepsy and postherpetic neuralgia trials). Undertreated hypothyroidism independently causes fatigue, cognitive slowing, and weight gain. Because the symptom lists overlap, a patient who feels worse after starting gabapentin should have thyroid function rechecked before either drug is blamed by default. A TSH within target range points toward gabapentin as the more likely explanation; a TSH outside target range means the levothyroxine dose needs review regardless of what else has changed.

Special populations

Older adults. Both hypothyroidism prevalence and gabapentin prescribing increase with age, so this combination is common in older patients. Reduced renal function affects gabapentin clearance and often requires a lower gabapentin dose, per the label's renal dosing guidance. Declining renal function does not directly change levothyroxine pharmacokinetics, but polypharmacy in older adults raises the general risk of timing errors and missed doses, which is a more likely source of thyroid instability than the drug interaction itself.

Pregnancy. Levothyroxine requirements typically rise during pregnancy, and TSH is monitored more frequently in that setting under professional guidelines. Gabapentin use in pregnancy requires an individualized risk-benefit discussion with the prescribing clinician; this article does not substitute for that conversation.

Malabsorption conditions. Celiac disease, short bowel syndrome, and bariatric surgery history already compromise levothyroxine absorption. In these patients, wider dosing separation between levothyroxine and any other oral medication, including gabapentin, is a reasonable precaution.

When a dose adjustment might be needed

In most patients, starting gabapentin does not require a levothyroxine dose change. A dose adjustment becomes relevant if:

TSH rises above the target range at a scheduled recheck, in which case the standard approach is a small levothyroxine dose increase followed by a repeat TSH in six to eight weeks.

The patient switches from gabapentin to an enzyme-inducing anticonvulsant such as phenytoin or carbamazepine. That switch is the scenario that actually calls for proactive levothyroxine monitoring, since the new drug (not gabapentin) carries the known interaction.

The patient stops gabapentin after their levothyroxine dose was adjusted for an unrelated reason during co-therapy. A follow-up TSH confirms the current dose is still appropriate.

A practical daily schedule

One workable pattern, for illustration only and not a personalized dosing instruction:

Take levothyroxine on waking, on an empty stomach, with water. Wait at least 30 to 60 minutes before breakfast and before the first gabapentin dose of the day. Space remaining gabapentin doses through the day as prescribed. If levothyroxine is taken at bedtime instead of morning, separate it from the last gabapentin dose by two to four hours.

Any individual dosing schedule should be set with the prescribing clinician, particularly if other medications, supplements, or GI conditions are involved.

Evidence-status assessment: levothyroxine and gabapentin

What is established, what is plausible, and what is not

Established: gabapentin and levothyroxine are cleared through different pathways, and gabapentin does not appear on either drug's label as an agent affecting the other's metabolism. Plausible but unproven: the mechanistic separation predicts a low risk of clinically meaningful interaction, but no dedicated interaction study confirms this in practice. Not established: any claim about a precise magnitude of absorption change, or a guarantee that TSH will remain stable in every patient adding gabapentin to a levothyroxine regimen. Patients with unexplained TSH shifts after starting gabapentin should not assume the two drugs are unrelated; they should have it checked rather than assumed either way.

When to seek care

Contact the prescribing clinician for new or worsening fatigue, unexplained weight change, palpitations, or heat or cold intolerance after any medication change, rather than adjusting either drug independently. Seek urgent care for symptoms of severe hypothyroidism (confusion, significant swelling, very slow heart rate) or for signs of a serious gabapentin reaction such as severe dizziness, difficulty breathing, or signs of an allergic reaction.